Innate immune responses are critical for the initial defense against influenza A virus (IAV) infection. However, an exaggerated cytokine response, often termed a “cytokine storm,” contributes significantly to disease severity and mortality. Among the key mediators of this response are interferon lambda (IFN-l), which play pivotal roles in antiviral defense, particularly in epithelial cells lining the respiratory tract. Despite their importance, the mechanisms governing IFN-l overproduction during IAV infection remain poorly understood. This study reveals that IAV infection induces robust expression of IFN-l primarily through a RIG-I-dependent pathway in alveolar epithelial cells (A549). Yet, paradoxically, signaling downstream of IFN-l—specifically phosphorylation of STAT1—is severely inhibited in infected cells. This suppression is driven by the upregulation of suppressor of cytokine signaling-1 (SOCS-1), a potent negative regulator of JAK-STAT signaling. Notably, SOCS-1 induction occurs early during infection and is independent of cytokine feedback loops, both in vitro and in vivo. Using transgenic mouse models and genetic interventions, we demonstrate that disrupting SOCS-1 expression or expressing a constitutively active form of STAT1 significantly reduces IFN-l production. Furthermore, we uncover a compensatory mechanism: inhibition of IFN-l signaling leads to activation of NF-kB, which in turn enhances IFN-l transcription. These findings suggest that viral-induced SOCS-1 triggers a maladaptive host response, where impaired IFN-l signaling results in excessive IFN-l production as a failed attempt to bolster antiviral defense. This cycle ultimately leads to immunopathology without effective viral control, highlighting SOCS-1 as a central player in the dysregulation of innate immunity during severe influenza infection.
The Role of RIG-I in Inducing IFN-l Expression during IAV Infection
To understand how IAV triggers the innate immune response, we investigated the molecular pathways leading to IFN-l expression in human alveolar epithelial A549 cells. Microarray analysis revealed significant upregulation of IFN-l family members—IL-28A, IL-28B, and IL-29—following infection with A/WSN/33 (H1N1) virus. Quantitative RT-PCR confirmed these findings in both A549 cells and mouse lung tissues, while ELISA detected elevated IL-29 protein levels in culture supernatants. Importantly, heat-inactivated virus (56°C) or denatured virus (65°C) failed to induce IFN-l, indicating that live viral replication is required for robust expression.RF9 manufacturer Transfection experiments using total RNA isolated from infected cells demonstrated that both viral genomic RNA and newly synthesized viral transcripts contribute to IFN-l induction. Critically, removal of the 5′-triphosphate group on viral RNA via calf intestine alkaline phosphatase (CIAP) drastically reduced IFN-l expression, implicating the 5′-triphosphate moiety as a key pathogen-associated molecular pattern (PAMP). To identify the sensor responsible, we used shRNA-mediated knockdown of RIG-I, TLR3, and MDA5. Silencing RIG-I led to a marked reduction in IFN-l production, whereas TLR3 knockdown had only a minor effect, and MDA5 silencing showed no impact. These results indicate that RIG-I is the dominant sensor for initiating IFN-l expression in response to IAV, acting through recognition of viral RNA with 5′-triphosphate ends.
Inhibition of IFN-l-Induced STAT1 Phosphorylation by Viral Infection
Despite strong induction of IFN-l, downstream signaling remains dysfunctional during IAV infection. We examined whether IFN-l could activate its canonical JAK-STAT pathway in A549 cells. Stimulation with recombinant IL-29 induced dose-dependent phosphorylation of STAT1, confirming functional receptor signaling in uninfected cells. However, in IAV-infected cells, STAT1 phosphorylation was dramatically suppressed even when exposed to exogenous IL-29. Time-course analysis showed that this inhibition became pronounced after 15 hours post-infection, coinciding with peak viral replication. Importantly, treatment with conditioned medium from infected cells did not recapitulate the suppression, ruling out soluble inhibitors released into the culture environment. Instead, the defect appears intrinsic to infected cells, suggesting that viral proteins actively interfere with the IFN-l signaling cascade. This observation implies that IAV has evolved mechanisms to block autocrine and paracrine IFN-l signaling, thereby undermining the antiviral state despite high cytokine levels.
SOCS-1 Upregulation Mediates Suppression of STAT1 Activation
Given the critical role of SOCS-1 as a negative regulator of cytokine signaling, we assessed its expression during IAV infection. Quantitative RT-PCR showed rapid and sustained upregulation of SOCS-1 mRNA early in infection, followed by a decline at later stages. Western blotting confirmed a consistent increase in SOCS-1 protein levels throughout infection. Immunofluorescence staining localized SOCS-1 expression specifically to IAV-infected cells, with concomitant loss of STAT1 phosphorylation. Notably, supernatants from infected cultures could induce SOCS-1 expression only at later time points, indicating that SOCS-1 induction is initially triggered directly by viral infection rather than by secreted cytokines. To determine functional relevance, we used shRNA to knock down SOCS-1 in A549 cells. In SOCS-1-deficient cells, STAT1 phosphorylation was markedly enhanced upon IAV infection, demonstrating that SOCS-1 acts as a direct inhibitor of IFN-l signaling. These data establish that IAV-induced SOCS-1 is a key mediator of impaired STAT1 activation, contributing to the failure of effective antiviral signaling.
Disruption of IFN-l Signaling Leads to NF-kB Activation and Excessive IFN-l Production
We next explored how suppression of IFN-l signaling results in increased IFN-l expression. Our hypothesis was that blocking JAK-STAT signaling might relieve negative feedback and allow alternative transcription factors to drive IFN-l gene expression. Indeed, we found that forced activation of STAT1 via constitutively active STAT1-2C mutant significantly reduced IFN-l production during IAV infection. Similarly, SOCS-1 knockdown in A549 cells led to decreased IL-29 and IL-28A/B mRNA levels. Surprisingly, despite reduced IFN-l, antiviral ISG expression (e.g., OAS-2, Mx1) remained intact, suggesting that the antiviral response is preserved even when IFN-l is lower. Mechanistically, we observed that disruption of IFN-l signaling led to enhanced NF-kB activity. Luciferase reporter assays and Western blotting revealed increased NF-kB-driven transcription and degradation of IkBα, the inhibitor of NF-kB, in SOCS-1-deficient or STAT1-activated cells. Conversely, SOCS-1 overexpression enhanced NF-kB activation. Immunofluorescence confirmed nuclear translocation of p65 subunit of NF-kB in control cells but not in SOCS-1-ablated or STAT1-activated cells. These findings reveal a reciprocal relationship: suppression of IFN-l signaling by SOCS-1 unleashes NF-kB, which then drives further IFN-l expression, creating a self-amplifying loop that results in pathological overproduction.
In Vivo Validation of SOCS-1’s Role in IFN-l Overproduction
To confirm these findings in a physiological context, we conducted in vivo studies using BALB/c mice infected with IAV. SOCS-1 protein levels were consistently elevated in lung tissues during the first three days post-infection, paralleling reduced STAT1 phosphorylation.Phospho-Smad1/5/9 Antibody Cancer Concurrently, NF-kB activity increased, as evidenced by diminished IkBα levels.PMID:35067796 Interestingly, SOCS-1 expression preceded that of IFN-l, supporting the idea of a cytokine-independent induction mechanism. We administered membrane-permeable peptides mimicking SOCS-1’s kinase inhibitory region (SOCS-1-KIR) or a competitive inhibitor of JAK2 (pJAK2) to modulate signaling. Mice treated with SOCS-1-KIR exhibited significantly higher IFN-l levels, while those treated with pJAK2 showed reduced IFN-l expression. Moreover, SOCS-1-KIR treatment worsened body weight loss, whereas pJAK2 improved survival outcomes. These results confirm that SOCS-1-mediated suppression of IFN-l signaling promotes excessive IFN-l production in vivo, contributing to immunopathology.
Functional Impact of SOCS-1 Knockdown in Transgenic Mice
To further dissect the role of SOCS-1 in IFN-l regulation, we generated SOCS-1-knockdown transgenic mice using shRNA technology. These mice displayed enhanced STAT1 phosphorylation and reduced NF-kB activation upon IAV infection. Consequently, IFN-l expression was significantly lower in transgenic animals compared to wild-type controls. Histological analysis revealed attenuated lung inflammation in SOCS-1-deficient mice, and they exhibited less body weight loss and reduced viral loads. These findings indicate that dampening SOCS-1 expression improves antiviral immunity and reduces tissue damage despite lower IFN-l levels. The results underscore that excessive IFN-l production is not beneficial and may be detrimental, reinforcing the notion that SOCS-1 acts as a rheostat whose overactivity disrupts immune homeostasis.
Conclusion and Implications for Influenza Pathogenesis
This study uncovers a novel mechanism by which IAV exploits host regulatory networks to induce pathological IFN-l overproduction. By inducing SOCS-1, the virus suppresses IFN-l signaling, triggering a compensatory activation of NF-kB that drives further IFN-l synthesis. This creates a vicious cycle: more IFN-l is produced, but its signaling is blocked, resulting in ineffective antiviral responses and heightened inflammation. The imbalance between cytokine production and functional signaling underlies the immunopathology seen in severe influenza. Targeting SOCS-1 or enhancing STAT1 activity may represent promising therapeutic strategies to restore immune balance and reduce disease severity. These findings highlight the complexity of host-virus interactions and emphasize the need for therapies that go beyond simple immune stimulation to correct dysregulated signaling pathways.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com